Voyager Therapeutics (VYGR) EPS (Weighted Average and Diluted) (2018 - 2025)
Historic EPS (Weighted Average and Diluted) for Voyager Therapeutics (VYGR) over the last 8 years, with Q3 2025 value amounting to -$0.47.
- Voyager Therapeutics' EPS (Weighted Average and Diluted) fell 19375.0% to -$0.47 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.17, marking a year-over-year decrease of 43384.62%. This contributed to the annual value of -$1.13 for FY2024, which is 13804.71% down from last year.
- Per Voyager Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.47 for Q3 2025, which was down 19375.0% from -$0.57 recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $2.94 in Q1 2023 and a low of -$0.8 during Q2 2021
- In the last 5 years, Voyager Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.51 in 2023 and averaged -$0.15.
- In the last 5 years, Voyager Therapeutics' EPS (Weighted Average and Diluted) tumbled by 51333.33% in 2022 and then surged by 62500.0% in 2023.
- Quarter analysis of 5 years shows Voyager Therapeutics' EPS (Weighted Average and Diluted) stood at $0.15 in 2021, then tumbled by 513.33% to -$0.62 in 2022, then skyrocketed by 291.94% to $1.19 in 2023, then tumbled by 150.42% to -$0.6 in 2024, then grew by 21.67% to -$0.47 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.47 in Q3 2025, compared to -$0.57 in Q2 2025 and -$0.53 in Q1 2025.